CoChat

Microbiota-centered interventions to boost immune checkpoint blockade therapies

Open access
Almonte, Andrew A., Thomas, Simon, Zitvogel, Laurence · 2025 · Journal of Experimental Medicine

The DOI matches its Crossref record; 139 of the 140 references it cites were found in a registry or an index, and 1 are not checked yet; 68 of the 183 sources its claims cite were checked for support.

Abstract

Immune checkpoint blockade therapies have markedly advanced cancer treatment by invigorating antitumor immunity and extending patient survival. However, therapeutic resistance and immune-related toxicities remain major concerns. Emerging evidence indicates that microbial dysbiosis diminishes therapeutic response rates, while a diverse gut ecology and key beneficial taxa correlate with improved treatment outcomes. Therefore, there is a growing understanding that manipulating the gut microbiota could boost therapy efficacy. This review examines burgeoning methods that target the gut microbiome to optimize therapy and innovative diagnostic tools to detect dysbiosis, and highlights challenges that remain to be addressed in the field.

Verified 2026-11-19 · 1 reference not checked yet

Overview

CoChat Summary

TL;DR

This review argues that gut microbial dysbiosis limits immune checkpoint blockade (ICB) efficacy and increases immune-related adverse events, while microbiota-centered interventions (MCIs) such as FMT, probiotics, prebiotics, synbiotics, and diet may boost responses. It surveys diagnostic tools for dysbiosis and ongoing clinical trials, but concludes that standardized definitions, mechanistic clarity, and larger validation studies are still needed.

Key findings

  • Antibiotic exposure near ICB initiation is linked to worse outcomes; a meta-analysis of ∼46,000 patients found the most pronounced detrimental effect when antibiotics were taken from 60 days before to 42 days after ICB start.
  • Specific taxa correlate with response, including *Akkermansia muciniphila*, *Faecalibacterium prausnitzii*, and *Bifidobacterium* spp.; *A. muciniphila* shows a nonlinear effect, with both absence and abundance >77th percentile (>4.779%) associated with dismal overall survival in lung and urinary tract malignancies.
  • FMT trials report promising signals: in the randomized TACITO trial, FMT plus axitinib/pembrolizumab in mRCC improved 1-year PFS (66.7% vs 35.0%, P = 0.036), ORR (54% vs 28%), and median PFS (14.2 vs 9.2 mo); a phase I melanoma trial of healthy-donor FMT with anti-PD-1 achieved ORR 65%.
  • Probiotic CBM588 supplementation in mRCC was associated with improved ORR (74% vs 20%) and 6-month PFS (84% vs 60%), while the MET-4 consortium trial showed a response rate of ∼35% (6/17) vs 14% (1/7) in control, with clinical benefit in 53% vs 20%.

Methods

  • Narrative review focused on PD-1 blockade and anti-CTLA-4 therapies, synthesizing preclinical and clinical evidence on the gut microbiome’s role in ICB efficacy and toxicity.
  • Discusses diagnostic approaches including 16S rRNA sequencing, shotgun metagenomics, alpha/beta diversity, machine learning classifiers, GMHI, and TOPOSCORE, which uses 37 resistance-linked species (SIG1) and 45 response-linked species (SIG2).
  • Summarizes MCIs—diet, FMT, probiotics, prebiotics, synbiotics—and tabulates ongoing clinical trials from ClinicalTrials.gov combining these interventions with immunotherapy.

Limitations

  • The paper states there is no universally accepted definition of dysbiosis, and the precise nature of imbalance—taxonomic change versus disrupted host regulation—remains debated.
  • It notes that FMT mechanisms are only partially understood, donor screening carries pathogen-transmission risk, and donor–recipient compatibility factors are poorly understood; probiotic safety concerns include bacteremia risk and possible negative effects on ICB efficacy.
  • Evident from the text: this is a narrative review without systematic search or quantitative synthesis, and many cited MCI trials are ongoing, preliminary, or not yet recruiting, limiting definitive conclusions.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1084/jem.20250378

Cites

139 of 140 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

50 Valid · 5 Not valid · 83 Not checked · 31 Own results and interpretations

70 more claims · 36 with their cited sources checked

Create a free account to see all 169 claims and to verify the 112 references still open.

See all claims — free account
  • Probably not a substantial claim. 33
  • It may state two separate claims as one. 74
  • The quote only partly states this claim. 1

Create a free account to see these claims.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Each contradiction between two passages listed here was confirmed by an independent check.

2 of 2

Citations

Cites

Show all 140 references

Cited by

See all 20

Metadata

Authors
Almonte, A. A., Thomas, S., & Zitvogel, L.
Affiliations
Inserm (FR)
Corresponding author
Zitvogel, Laurence
Venue
Journal of Experimental Medicine
Published
2025-04-22
Volume
222
Issue
7
ISSN
  • 0022-1007 (ISSN-L)
  • 1540-9538
OpenAlex
W4409654026
Cited by
19
References
140
Citations by year
2026: 9 · 2025: 10
FWCI
2.23
Type
journal article
Language
en
Open access
Locations
  • The Journal of Experimental Medicine (publishedVersion)
  • PubMed (publishedVersion)
  • PubMed Central (submittedVersion)
Funders
  • Institut Gustave-Roussy
  • Daiichi Sankyo Europe
Topics
  • Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
  • Life Sciences › Agricultural and Biological Sciences › Food Science › Probiotics and Fermented Foods
Keywords
immune checkpoint blockade, gut microbiota, microbiota-targeted interventions, cancer immunotherapy, dysbiosis, treatment resistance, immune-related adverse events, antitumor immunity, microbiome diagnostics
MeSH terms
Gastrointestinal Microbiome, Immune Checkpoint Inhibitors, Animals, Humans, Immunotherapy, Neoplasms, Dysbiosis

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-07, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-07 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol and qwen3.8-omni-flash).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Microbiota-centered interventions to boost immune checkpoint blockade therapies. https://app.cochat.ai/papers/10.1084/jem.20250378
The paper
Almonte, A. A., Thomas, S., & Zitvogel, L. (2025). Microbiota-centered interventions to boost immune checkpoint blockade therapies. Journal of Experimental Medicine. https://doi.org/10.1084/jem.20250378

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.